1. Home
  2. SVM vs CGEM Comparison

SVM vs CGEM Comparison

Compare SVM & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silvercorp Metals Inc.

SVM

Silvercorp Metals Inc.

HOLD

Current Price

$11.52

Market Cap

2.1B

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$20.77

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SVM
CGEM
Founded
N/A
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
1.4B
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
SVM
CGEM
Price
$11.52
$20.77
Analyst Decision
Hold
Strong Buy
Analyst Count
1
8
Target Price
$10.50
$30.13
AVG Volume (30 Days)
2.1M
701.9K
Earning Date
05-25-2026
05-11-2026
Dividend Yield
0.22%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$36.87
N/A
Revenue Next Year
$35.34
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.00
$5.68
52 Week High
$15.77
$23.19

Technical Indicators

Market Signals
Indicator
SVM
CGEM
Relative Strength Index (RSI) 41.94 43.84
Support Level $9.66 $11.87
Resistance Level $11.48 $23.19
Average True Range (ATR) 0.57 0.92
MACD -0.22 -0.38
Stochastic Oscillator 0.61 30.77

Price Performance

Historical Comparison
SVM
CGEM

About SVM Silvercorp Metals Inc.

Silvercorp Metals Inc is engaged in the acquisition, exploration, development, and mining of mineral properties. The Company's producing mines are located in China, and current exploration and development projects are located in China, Ecuador and Kyrgyz Republic. The company operates in single segment. The Company mainly produces and sells silver, lead, zinc, gold and other metals. The company's producing projects are Ying Mining District, GC Mine; construction projects are El Domo; permitting project is BYP Mine; development project includes Condor, Tulkubash/Kyzyltash.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: